Gentian Diagnostics AS - Primary insider notification

03. Oct 2018 | 2 min read

(Oslo, Norway, October 03, 2018) Vatne Equity AS has acquired 135,526 shares in Gentian Diagnostics AS at an average price of NOK 59.14 per share. Henrik Krefting, CEO of Vatne Capital AS, which is the owner of Vatne Equity AS, is a Board Member of Gentian Diagnostics AS.

Following the share purchase, Vatne Equity AS will hold 1,735,340 shares in Gentian, corresponding to 11.27% of the outstanding shares. In addition, Lioness AS, a sister company of Vatne Equity AS, owns 150,000 shares in Gentian, corresponding to 0.97% of the outstanding shares. Following the share purchase, Vatne Equity AS and Lioness AS will together hold 1,885,340 shares in Gentian, corresponding to 12.25% of the outstanding shares.

This information is subject to the disclosure requirements set out in section 5-12 of the Norwegian Securities Trading Act.

Further information
Henrik Krefting
Chief Executive Officer, Vatne Capital AS
E-mail: hk@vatnecapital.com Cell Phone: +47 916 12 279

MeldingsID:  460597

You may also read


May 06, 2026 - Ole Sørlie

Gentian Diagnostics: First quarter 2026 report

Moss, 6 May 2026 Gentian Diagnostics ASA, a fast-growing developer and manufacturer of diagnostic tests,..

May 06, 2026 - Ole Sørlie

Gentian Diagnostics ASA terminates NT-proBNP assay development

Moss, 6 May 2026 Following a comprehensive review of performance data and market dynamics, Gentian..

May 06, 2026 - Ole Sørlie

Gentian Diagnostics: Ex dividend NOK 0.60 today

Moss, 6 May 2026 The shares in Gentian Diagnostics ASA will be traded ex dividend NOK 0.60 as of today. The..